other Cas9 orthologs may have different PAM requirements, such as those of S. thermophilus (5′-NNAGAA 22, 26 for CRISPR1 and 5′-NGGNG 28, 37 for CRISPR3) and Neisseria meningiditis (5′-NNNNGATT) 39 .
The RNA-guided nuclease function of CRISPR-Cas is reconstituted in mammalian cells through the heterologous expression of human codon-optimized Cas9 and the requisite RNA components [22] [23] [24] [25] . Furthermore, the crRNA and tracrRNA can be fused together to create a chimeric, single-guide RNA (sgRNA) 27 ( Fig. 1) . Cas9 can thus be re-directed toward almost any target of interest in immediate vicinity of the PAM sequence by altering the 20-nt guide sequence within the sgRNA.
Given its ease of implementation and multiplexing capacity, Cas9 has been used to generate engineered eukaryotic cells carrying specific mutations via both NHEJ and HDR [22] [23] [24] [25] 40 . Direct injection of sgRNA and mRNA encoding Cas9 into embryos has enabled the rapid generation of transgenic mice with multiple modified alleles 41, 42 . These results hold enormous promise for editing organisms that are otherwise genetically intractable.
Cas9 nucleases carry out strand-specific cleavage by using the conserved HNH and RuvC nuclease domains, which can be mutated and exploited for additional function 37 . An aspartate-to-alanine (D10A) mutation in the RuvC catalytic domain 27, 28 allows the Cas9 nickase mutant (Cas9n) to nick rather than cleave DNA to yield single-stranded breaks, and the subsequent preferential repair through HDR 22 can potentially decrease the frequency of unwanted indel mutations from off-target DSBs. Appropriately offset sgRNA pairs can guide Cas9n to simultaneously nick both strands of the target locus to mediate a DSB, thus effectively increasing the specificity of target recognition 43 . In addition, a Cas9 mutant with both DNAcleaving catalytic residues mutated has been adapted to enable transcriptional regulation in Escherichia coli 44 , demonstrating the potential of functionalizing Cas9 for diverse applications, such as recruitment of fluorescent protein labels or chromatinmodifying enzymes to specific genomic loci for reporting or modulating gene function.
Here we explain in detail how to use a human codonoptimized, nuclear localization sequence-flanked wild-type (WT) Cas9 nuclease or mutant Cas9 nickase to facilitate eukaryotic gene editing. We describe considerations for designing the 20-nt guide sequence, protocols for rapid construction and functional validation of sgRNAs and finally the use of the Cas9 nuclease to mediate both NHEJ-and HDR-based genome modifications in human embryonic kidney (HEK 293FT) and human stem cell (HUES9) lines (Fig. 3) . The Cas9 system can similarly be applied to other cell types and organisms, including humans 22, 23, 25 , mice 22, 41, 45 , zebrafish 45 , Drosophila 46 and Caenorhabditis elegans 47 .
Comparison with other genome editing technologies
As with other designer nuclease technologies such as ZFNs and TALENs, Cas9 can facilitate targeted DNA DSBs at specific loci of interest in the mammalian genome and stimulate genome editing via NHEJ or HDR. Cas9 offers several potential advantages over ZFNs and TALENs, including the ease of customization, higher targeting efficiency and the ability to facilitate multiplex genome editing. As custom ZFNs are often difficult to engineer, we will primarily compare Cas9 with TALEN.
Ease of customization. Cas9 can be easily retargeted to new DNA sequences by simply purchasing a pair of oligos encoding the 20-nt guide sequence. In contrast, retargeting of TALEN for a new DNA sequence requires the construction of two new TALEN genes. Although a variety of protocols exist for TALEN construction 14, 17, 48, 49 , it takes substantially more hands-on time to construct a new pair of TALENs. Cleavage pattern. WT S. pyogenes Cas9 (SpCas9) is known to make a blunt cut between the 17th and 18th bases in the target sequence (3 bp 5′ of the PAM) 27 . Mutating catalytic residues in either the RuvC or the HNH nuclease domain of SpCas9 converts the enzyme into a DNA nicking enzyme 22, 27 . In contrast, TALENs cleave nonspecifically in the 12-24-bp linker between the pair of TALEN monomer-binding sites 50 .
• can be repaired in one of two ways. In the error-prone NHEJ pathway, the ends of a DSB are processed by endogenous DNA repair machinery and rejoined, which can result in random indel mutations at the site of junction. Indel mutations occurring within the coding region of a gene can result in frameshifts and the creation of a premature stop codon, resulting in gene knockout. Alternatively, a repair template in the form of a plasmid or ssODN can be supplied to leverage the HDR pathway, which allows high fidelity and precise editing. Single-stranded nicks to the DNA can also induce HDR.
Editing efficiency. SpCas9 and TALENs have both been shown to facilitate efficient genome editing in a variety of cell types and organisms. However, owing to the ease of targeting, Cas9 can be used to target multiple genomic loci simultaneously, by co-delivering a combination of sgRNAs to the cells of interest.
Limitations of the Cas9 system
Cas9 can be targeted to specific genomic loci via a 20-nt guide sequence on the sgRNA. The only requirement for the selection of Cas9 target sites is the presence of a PAM sequence directly 3′ of the 20-bp target sequence. Each Cas9 ortholog has a unique PAM sequence; for example, SpCas9 requires a 5′-NGG PAM sequence. This PAM requirement does not severely limit the targeting range of SpCas9-in the human genome, such target sites can be found on average every 8-12 bp (refs. 22,51) . In addition to the targeting range, another possible limitation is the potential for off-target mutagenesis; please see Boxes 1 and 2 for details and strategies on minimizing offtarget modifications.
Experimental design
Target selection for sgRNA. The specificity of the Cas9 nuclease is determined by the 20-nt guide sequence within the sgRNA. For the S. pyogenes system, the target sequence (e.g., 5′-GTC ACCTCCAATGACTAGGG-3′) must immediately precede (i.e., be 5′ to) a 5′-NGG PAM, and the 20-nt guide sequence base pairs with the opposite strand to mediate Cas9 cleavage at ~3 bp upstream of the PAM (Figs. 1 and 4a top strand example) . Note
• that the PAM sequence is required to immediately follow the target DNA locus, but that it is not a part of the 20-nt guide sequence within the sgRNA.
Thus, there are two main considerations in the selection of the 20-nt guide sequence for gene targeting: (i) the 5′-NGG PAM for S. pyogenes Cas9 and (ii) the minimization of off-target activity 51, 52 . We provide an online CRISPR Design Tool (http:// tools.genome-engineering.org) that takes a genomic sequence of interest and identifies suitable target sites. To experimentally assess off-target genomic modifications for each sgRNA, we also provide computationally predicted off-target sites (for a detailed discussion, see Box 1) for each intended target, ranked according to our quantitative specificity analysis on the effects of base-pairing mismatch identity, position and distribution. For increased targeting specificity, an alternative strategy using the D10A nickase mutant of Cas9 (Cas9n) along with a pair of sgRNAs may be used. The design criteria for orientation and spacing of such sgRNA pairs are described in Box 2.
The CRISPR Design Tool provides the sequences for all oligos and primers necessary for (i) preparing the sgRNA constructs, (ii) assaying target modification efficiency and (iii) assessing cleavage at potential off-target sites. It is worth noting that because the U6 RNA polymerase III promoter used to express the sgRNA prefers a guanine (G) nucleotide as the first base of its transcript 59 , an extra G is appended at the 5′ of the sgRNA where the 20-nt guide sequence does not begin with G (Fig. 4b,c) . On rare occasions, certain sgRNAs may not work for reasons yet unknown; therefore, we recommend designing at least two sgRNAs for each locus and testing their efficiencies in the intended cell type.
Approaches for sgRNA construction and delivery. Depending on the desired application, sgRNAs can be delivered as either PCR amplicons containing an expression cassette (Fig. 4b) or sgRNA-expressing plasmids (Fig. 4c) . PCR-based sgRNA delivery appends the custom sgRNA sequence onto the reverse PCR primer used to amplify a U6 promoter template (Fig. 4b) . The resulting amplicon could be co-transfected with a Cas9 expression plasmid pSpCas9. This method is optimal for rapid screening of multiple candidate sgRNAs, as cell transfections for functional testing can be performed shortly after obtaining the sgRNA-encoding primers. Because this simple method obviates the need for plasmid-based cloning and sequence verification, it is well suited for testing or co-transfecting a large number of sgRNAs for generating large knockout libraries or other scalesensitive applications. Note that the sgRNA-encoding primers are over 100 bp long, compared with the ~20-bp-long oligos required for plasmid-based sgRNA delivery. Construction of an expression plasmid for sgRNA is also simple and rapid, involving a single cloning step with a pair of partially complementary oligonucleotides. The oligo pairs encoding the 20-nt guide sequences are annealed and ligated into a plasmid (pSpCas9(BB), Fig. 4c ) bearing both Cas9 and the remainder of the sgRNA as an invariant scaffold immediately following the oligo cloning site. The transfection plasmids can also be modified to enable virus production for in vivo delivery. For these approaches, the following plasmids are used within this protocol: Cas9 alone (pSpCas9) or Cas9 with an invariant sgRNA scaffold and cloning sites for inserting a guide sequence (pSpCas9(BB)). For the backbone cloning construct, we have also fused 2A-GFP or 2A-Puro to Cas9 to allow screening or selection of transfected cells (pSpCas9(BB)-2A-GFP or pSpCas9(BB)-2A-Puro, respectively). Finally, we provide pSpCas9n(BB), a D10A nickase mutant of Cas9 for HDR and for double-nicking applications (Box 2), along with the 2A-GFP and 2A-Puro fusion constructs (pSpCas9n(BB)-2A-GFP, pSpCas9n(BB)-2A-Puro).
In addition to PCR and plasmid-based delivery methods, Cas9 and sgRNAs can be introduced into cells as mRNA and RNA, respectively.
Design of repair template. Traditionally, targeted DNA modifications have required the use of plasmid-based donor repair templates that contain homology arms flanking the site of alteration 54, 55 (Fig. 2) . The homology arms on each side can vary in length, but are typically longer than 500 bp (refs. 55,56) . This method can be used to generate large modifications, including insertion of reporter genes such as fluorescent proteins or antibiotic resistance markers. The design and construction of targeting plasmids has been described elsewhere 57 .
More recently, ssODNs have been used in place of targeting plasmids for short modifications within a defined locus without cloning 32 . To achieve high HDR efficiencies, ssODNs contain flanking sequences of at least 40 bp on each side that are homologous to the target region, and they can be oriented in either the sense or antisense direction relative to the target locus. It is worth noting that targeting efficiencies can vary widely
Box 1 | Considerations for off-target cleavage activities
Similarly to other nucleases, Cas9 can cleave off-target DNA targets in the genome at reduced frequencies 51, 52, 61 . The extent to which a given guide sequence exhibits off-target activity depends on a combination of factors including enzyme concentration and the abundance of similar sequences in the target genome. For routine application of Cas9, it is important to consider ways to minimize the degree of off-target cleavage and also to be able to detect the presence of off-target cleavage 51, 52, 61 .
Minimizing off-target activity. For application in cell lines, we recommend following two steps to reduce the degree of off-target genome modification. First, by using our online CRISPR Design Tool, it is possible to computationally assess the likelihood of a given guide sequence to have off-target sites. These analyses are performed through an exhaustive search in the genome for off-target sequences that are similar to the guide sequence. Comprehensive experimental investigation of the effect of mismatching bases between the sgRNA and its target DNA revealed that mismatch tolerance is (i) position dependent: the 8-14 bp on the 3′ end of the guide sequence is less tolerant of mismatches than the 5′ bases; (ii) quantity dependent: in general, more than three mismatches are not tolerated; (iii) guide sequence dependent: some guide sequences are less tolerant of mismatches than others; and (iv) concentration dependent: off-target cleavage is highly sensitive to the transfected amounts, as well as relative ratios of Cas9 and sgRNA 51 . As shown in the illustration (adapted with permission from ref. 51 ; error bars show s.e.m. (n = 3)), Cas9 can exhibit off-target cleavage in the genome, which may be minimized by carefully titrating the amount of pSpCas9 DNA transfected. The CRISPR Design Tool integrates these criteria to provide predictions for likely off-target sites in the target genome. We also recommend titrating the amount of Cas9 and sgRNA expression plasmid to minimize off-target activity.
Detection of off-target activities. We have found experimentally that Cas9 can cleave at genomic off-target sites with either 5′-NGG or 5′-NAG PAMs. By using our CRISPR-targeting web tool, it is possible to generate a list of the most likely off-target sites, as well as primers for performing SURVEYOR or sequencing analysis of those sites. For isogenic clones generated using Cas9, we strongly recommend sequencing candidate off-target sites to check for any undesired mutations. It is worth noting that there may be off-target modifications in sites that are not included in the predicted candidate list, and full genome sequencing should be performed to completely verify the absence of off-target sites. Furthermore, in multiplex assays where several DSBs are induced within the same genome, there may be low rates of translocation events and they can be evaluated by using a variety of techniques such as deep sequencing 62 . depending on cell type, target locus, type of repair donor and location of modification relative to the DSB site. As a rule of thumb, single-base correction rates drop approximately fourfold at 100 bp away from the DSB site, and beyond 200 bp away drug selection markers may be required 58 .
Clonal isolation of cell lines. Isolation of clonal cell lines with specific modifications is often desired. This can be achieved after transfection by isolating single cells through either FACS (Steps 54-65) or serial dilutions (Steps 66-70), followed by an expansion period to establish a new clonal cell line. It is worth noting that cell types can vary substantially in their responses to single-cell isolation, and literature specific to the cell type of interest should be consulted.
Functional testing. SURVEYOR nuclease assay.
In cells cotransfected with a pair of sgRNAs to mediate a genomic (micro)deletion or inversion, indel mutations can be detected either by the SURVEYOR nuclease assay 59 or by sequencing (Fig. 5a ). Our online CRISPR Design Tool provides recommended primers for both approaches. However, SURVEYOR or sequencing primers can also be designed manually to amplify the region of interest from genomic DNA. Custom primers are chosen using the National Center for Biotechnology Information (NCBI) Primer-BLAST in order to avoid nonspecific amplification. SURVEYOR primers should be designed to amplify 200-400 bp on either side of the Cas9 target (for a total amplicon 400-800 bp long) to allow clear visualization of cleavage bands by gel electrophoresis (Fig. 5b) . To prevent excessive primer dimer formation, SURVEYOR primers should be designed to be typically 18 to 25 nt long with melting temperatures of ~60 °C. For SURVEYOR assay or sequencing analysis, we recommend testing that each pair of candidate primers produces a single PCR product, as well as testing for the absence of nonspecific cleavage during the SURVEYOR nuclease digestion process (Fig. 5) . Plasmid-or ssODN-mediated HDR. HDR can be detected via PCR amplification, followed by either sequencing of the modified region or restriction-fragment length polymorphism (RFLP) analysis. PCR primers for these purposes should anneal outside the region spanned by the homology arms to avoid false detection of residual repair template (primers HDR-Fwd and HDR-Rev; Table 1 and Fig. 6a ). For ssODN-mediated HDR, SURVEYOR PCR primers may be used. Either the WT Cas9 nuclease or mutant Cas9 nickase can be used to mediate HDR, although the efficiency of the latter can vary widely by cell type.
Detection of indels or HDR by sequencing. Targeted genome modifications can also be detected by either Sanger or deep sequencing. For the former, genomic DNA from the modified region can be amplified with either SURVEYOR or HDR primers. Amplicons should be subcloned into a plasmid such as pUC19 for transformation, and individual colonies should be sequenced to reveal the clonal genotype.
Alternatively, deep sequencing is suitable for sampling a large number of samples or target sites. NGS primers are designed for shorter amplicons, typically in the 100-200-bp size range.
Box 2 | Double-nicking strategy for minimizing off-target mutagenesis
To minimize off-target activity, a double nicking strategy can be used to introduce DSBs at the target site 43 . Whereas the WT Cas9 nuclease is guided by an sgRNA to mediate a DSB at the target locus, the D10A mutant Cas9 nickase (Cas9n) can be specified by a pair of appropriately spaced and oriented sgRNAs to simultaneously introduce single-stranded nicks on both strands of the target DNA. The DSBs from double nicking are then repaired via NHEJ and result in indel formation with similar levels of efficiency to that of WT Cas9. As single-stranded nicks are repaired without indel formation, DSBs would only occur if both sgRNAs are able to locate target sequences within a defined space. Thus, this strategy effectively doubles the number of bases that need to be specifically recognized at the target site and significantly increases the specificity of genome editing.
To facilitate efficient double nicking, the pair of sgRNAs must be designed such that 5′ overhangs are generated upon nicking. The target loci for the sgRNA pairs must also be offset with an optimal gap of 0-20 bp (see illustration: target DNA loci, blue N′s; PAM, pink; predicted cleavage sites on each strand, red triangles) 43 . The expression constructs for sgRNA pairs can be prepared by the PCR-based method as described for sgRNAs (Step 5A). The sgRNAs can then be combined at 1:1 ratio and introduced along with Cas9n by using identical procedures as for WT Cas9 and sgRNAs (Step 9, 20 ng for each sgRNA). Editing achieved by using this double-nicking strategy can be similarly detected using SURVEYOR assay or DNA sequencing. In addition to facilitating DSB-and NHEJ-mediated mutagenesis, double nicking can also be used to promote HDR with comparable efficiency as WT Cas9.
A web tool to help with the identification of suitable sgRNA pairs for double nicking can be accessed at http://tools.genomeengineering.org. 
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For the detection of NHEJ mutations, it is important to design primers situated at least 50 bp from the Cas9 target site to allow for the detection of longer indels. For larger deletions mediated by multiple sgRNAs, priming sites should be designed outside the deleted region. We provide guidelines for a two-step PCR fusion method to attach bar-coded sequencing adaptors for multiplex deep sequencing. We recommend the Illumina platform for its generally low levels of false positive indel detection. By comparison, Ion Torrent is less suitable for indel analysis owing to high sequencing error rate with homo-polymers 60 . Detailed descriptions of NGS optimization and troubleshooting can be found in the Illumina user manual. Off-target indel analysis (Box 1) can then be performed through read-alignment programs such as ClustalW, Geneious or simple custom sequence analysis scripts. 
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2|
Order necessary oligos and primers as specified by the online tool. If the cleavage site is chosen manually, the oligos or primers should be designed as described in Figure 4b ,c.
Design of the ssoDn template (optional)
• tIMInG 1 h 3| Design and order custom ssODN. Purchase either the sense or antisense ssODN directly from IDT or the preferred supplier. We recommend manually designing homology arms of at least 40 nt on either side and preferably 90 nt for optimal HDR efficiency. It is not necessary to PAGE-purify the ssODN.
4|
Resuspend and dilute ssODN ultramers to a final concentration of 10 µM. Do not combine or anneal the sense and antisense ssODNs. Store them at −20 °C.
preparation of sgrna expression construct 5| To generate the sgRNA expression construct, use either the PCR expression cassette (option A) or the plasmid-based procedure (option B).
(a) Generation of the sgrna expression construct by pcr amplification • tIMInG 2 h (i) Preparation of diluted U6 PCR template. We recommend using pSpCas9(BB) or pSpCas9n(BB) (supplementary Data 2) as a PCR template, but any U6-containing plasmid can be used. Dilute the template with ddH 2 O to a concentration of 10 ng µl −1 . Note that if a plasmid or cassette already containing a U6-driven sgRNA is used as a template, a gel extraction will need to be performed after PCR (Step 5A(iv)), using the QIAquick gel extraction kit according to the manufacturer's instructions, to ensure that the product contains only the intended sgRNA and no trace of sgRNA carryover from the template. (ii) Preparation of diluted PCR primers. Dilute the U6-Fwd and U6-Rev (designed either using the CRISPR Design Tool or by hand and unique for each sgRNA, Step 1) primers (  crItIcal step To minimize error in amplifying sgRNAs, it is important to use a high-fidelity polymerase.
Other high-fidelity polymerases, such as PfuUltra II (Agilent) or Kapa HiFi (Kapa Biosystems), may be used as a substitute.
(iv) Perform a PCR by using the following cycling conditions: (vii) Incubate the PlasmidSafe reaction at 37 °C for 30 min, followed by 70 °C for 30 min.  pause poInt After PlasmidSafe treatment, the reaction can be stored at −20 °C for at least 1 week. (viii) Transformation. Transform the PlasmidSafe-treated plasmid into a competent E. coli strain, according to the protocol supplied with the cells. We recommend the Stbl3 strain for quick transformation. Briefly, add 2 µl of the product from
Step 5B(vii) into 20 µl of ice-cold chemically competent Stbl3 cells, incubate the mixture on ice for 10 min, heat-shock it at 42 °C for 30 s and return it immediately to ice for 2 min. Add 100 µl of SOC medium and plate it onto an LB plate containing 100 µg ml −1 ampicillin. Incubate it overnight at 37 °C. Note that it is not necessary to incubate competent cells for the outgrowth period after heat shock when you are transforming ampicillinresistant plasmids.
(ix) Day 2: inspect the plates for colony growth. Typically, there are no colonies on the negative control plates (ligation of BbsI-digested pSpCas9(BB) alone without annealed sgRNA oligo insert), and there are tens to hundreds of colonies on the pSpCas9(sgRNA) (sgRNA inserted into pSpCas9(BB)) cloning plates. ? trouBlesHootInG (x) From each plate, pick two or three colonies to check for the correct insertion of sgRNA. Use a sterile pipette tip to inoculate a single colony into a 3-ml culture of LB medium with 100 µg ml − 1 ampicillin. Incubate the culture and shake it at 37 °C overnight. (xi) Day 3: isolate the plasmid DNA from cultures by using a QIAprep spin miniprep kit according to the manufacturer's instructions. (xii) Sequence validation of CRISPR plasmid. Verify the sequence of each colony by sequencing from the U6 promoter using the U6-Fwd primer. Optional: sequence the Cas9 gene by using the Cbh-Fwd and SXRP002-007 primers listed in supplementary Data 1. Reference the sequencing results against the pSpCas9(BB) cloning vector sequence to check that the 20-nt guide sequence is inserted between the U6 promoter and the remainder of the sgRNA scaffold (Fig. 4c) 7| To passage, remove the medium and rinse the cells once by gently adding DPBS to the side of the vessel, so as not to dislodge the cells. Add 2 ml of TrypLE to a T75 flask, and incubate the mixture for 5 min at 37 °C. Add 10 ml of warm D10 medium to inactivate the trypsin, and transfer the cells to a 50-ml Falcon tube. Dissociate the cells by pipetting them up and down gently, and then reseed them into new flasks as necessary.  crItIcal step We typically passage cells every 2-3 d at a split ratio of 1:4 or 1:8, never allowing cells to reach more than 70% confluency. Cells are discarded upon reaching passage number 15.
8| Preparation of cells for transfection.
Plate the well-dissociated cells onto 24-well plates in D10 medium without antibiotics 16-24 h before transfection. Seed the cells at a density of 1.3 × 10 5 cells per well in a total volume of 500 µl. Scale up or down according to the cell line supplier's manual as needed.  crItIcal step Do not plate more cells than the recommended density, as doing so may reduce transfection efficiency.
9|
On the day of transfection, cells are optimal at 70-90% confluency. Cells can be transfected with Lipofectamine 2000 or the Amaxa SF cell line 4D-Nucleofector X kit according to the manufacturers' instructions. Transfections should be performed as follows: for sgRNAs cloned into pSpCas9(BB), transfect 500 ng of sequence-verified CRISPR plasmid (pSpCas9(sgRNA)); if you are transfecting more than one plasmid (Box 2), mix them at equimolar ratios and use no more than 500 ng of total DNA. For sgRNA amplified by PCR, mix the following:
pSpCas9 (Cas9 only) 400 ng sgRNA amplicon from Step 5A (each) 20 ng pUC19 (carrier DNA) Fill up total DNA to 500 ng  crItIcal step We recommend transfecting in technical triplicates for reliable quantification, and including transfection controls (e.g., GFP plasmid) to monitor transfection efficiency. pSpCas9(sgRNA)-2A-GFP or pSpCas9(sgRNA)-2A-Puro may be used in place of pSpCas9 if fluorescence sorting or drug selection, respectively, is desired. In addition, the pSpCas9(BB) cloning plasmid and/or the sgRNA amplicon may be transfected alone as a negative control for downstream functional assays.
10| Add Lipofectamine complex to the cells gently, as HEK 293FT cells can detach easily from the plate, which will result in a lower transfection efficiency.
11| Check cells after 24 h for transfection efficiency. The percentage of fluorescent cells in the transfection control (e.g., GFP) can be estimated by using a fluorescence microscope. Typically, more than 70% of cells are transfected.
? trouBlesHootInG 12| Supplement the culture medium with an additional 500 µl of warm D10 medium.  crItIcal step Add D10 very slowly to the side of the well, and do not use cold medium, as cells can detach easily. Puromycin selection can be applied at a concentration of 1−3 µg ml −1 for HEK 293FT cells (may vary depending on the cell line).
13|
Incubate the cells for a total of 48-72 h after transfection before passaging them for downstream applications or harvesting for indel analysis. 
co-transfection of crIspr plasmids and HDr templates into HeK 293Ft cells (optional)
•
18|
Prewarming plates for transfection. Add 1 ml of warm D10 medium into each well of a 12-well plate. Place the plates in the incubator to keep the medium warm.
19| Use option A in the table below for preparing the co-transfection of the HDR targeting plasmid with the Cas9 plasmid or option B for the co-transfection of ssODN with the Cas9 plasmid. To prepare transfection controls, see Step 9 . If an sgRNA is cloned into pSpCas9(BB)-2A-GFP, cells may also be sorted by fluorescence. If you are using Cas9 nickase to mediate HDR, substitute pSpCas9(sgRNA) with pSpCas9n(sgRNA) from
Step 5B(v).  crItIcal step For HDR applications, we recommend cloning sgRNA guides into one of the sgRNA expression plasmids described in
Step 5B, rather than using the PCR-based expression approach. 30| Maintaining HUES9 cells. We routinely maintain HUES9 cells (a hESC cell line) in feeder-free conditions with mTesR1 medium. Prepare mTeSR1 medium by adding the 5× supplement included with the basal medium and 100 µg ml − 1 Normocin.
31|
Prepare a 10-ml aliquot of mTeSR1 medium supplemented further with 10 µM ROCK inhibitor.
32|
Coating a tissue culture plate. Dilute cold GelTrex 1:100 in cold DMEM and coat the entire surface of a 100-mm tissue culture plate.
33|
Place the plate in an incubator for at least 30 min at 37 °C.
34| Thaw a vial of cells at 37 °C, transfer the cells to a 15-ml Falcon tube, add 5 ml of mTeSR1 medium and pellet at 200g for 5 min at room temperature.
35| Aspirate the GelTrex coating (
Step 32) and seed ~1 × 10 6 cells with 10 ml of mTeSR1 medium containing ROCK inhibitor from Step 31.
36|
Replace with mTeSR1 medium without ROCK inhibitor after 24 h and refeed daily.
37| Passaging cells.
Passage the cells before they reach 70% confluency.
38|
Aspirate the mTeSR1 medium and wash the cells once with DPBS.
39|
Dissociate the cells by adding 2 ml of Accutase and incubating them at 37 °C for 3-5 min.
40| Add 10 ml of mTeSR1 medium to the detached cells, transfer the mixture to a 15-ml Falcon tube and resuspend gently.
41|
Replate the cells onto GelTrex-coated plates in mTeSR1 medium with 10 µM ROCK inhibitor.
42|
Replace with normal mTeSR1 medium 24 h after plating.
43|
Transfection. We recommend culturing cells for at least 1 week after thawing and before transfecting by using the Amaxa P3 primary cell 4D Nucleofector kit.
44|
Refeed log-phase growing cells (50-70% confluency) with fresh medium 2 h before transfection. 
45|
47|
Remove the medium completely and resuspend it in 20 µl of S1-supplemented P3 nucleofection solution, per 2 × 10 5 cells.
48|
Pipette the resuspended cells with added DNA (Steps 9 and 19) into electroporation cuvettes and electroporate according to the suggested program. For 2 × 10 5 cells, we typically use 1 µg of total DNA.
49|
Gently plate the electroporated cells onto coated 100-mm plates supplemented with 10 µM ROCK inhibitor.
50|
Check transfection success (Steps 11 and 28) and refeed the cells daily with regular mTeSR1 medium beginning 24 h after nucleofection. Puromycin selection can be applied at a concentration of 0.5 µg ml −1 (may vary depending on the cell line). Typically, we observe >70% transfection efficiency with Amaxa nucleofection. 
54| Preparation of FACS media.
Cells can be sorted in regular D10 medium supplemented with penicillin-streptomycin.
The antibiotics-containing medium should be filtered through a 0.22-µM Steriflip filter. If fluorescence sorting is also required, phenol red-free DMEM or DPBS is substituted for normal DMEM.
55|
To 96-well plates, add 100 µl of D10 medium supplemented with penicillin-streptomycin per well.  crItIcal step Not all sorted cells may survive the FACS process or the subsequent outgrowth; therefore, the number of plates prepared and cells sorted may need to be adjusted to ensure an adequate number of clonal lines derived.
56| Preparation of cells for FACS.
Dissociate the cells (from Steps 11 or 28) by aspirating the medium completely and adding enough TrypLE to thinly cover the adherent layer of transfected cells. Incubate the mixture for 5 min at 37 °C and add 400 µl of warm D10 medium.
57|
Transfer the resuspended cells into a 15-ml Falcon tube and gently triturate 20 times.  crItIcal step Check under the microscope to ensure dissociation to single cells. 
63|
Inspect the colonies for "clonal" appearance 1 week after sorting: rounded colonies radiating from a central point.
Mark off the wells that are empty or that may have been seeded more than a single cell.
64|
When the cells are more than 60% confluent, prepare replica plates for passaging (one well for each clone) by adding 100 µl of D10 medium to each well in the replica plates. Dissociate the cells directly by pipetting up and down vigorously 20 times, and plate 20% of each of the resuspended volumes into the replica wells to keep the clonal lines. Change the medium every 2-3 d thereafter and passage accordingly.
65|
Use the remaining 80% of cells for DNA isolation and genotyping (Steps 71-74).
Isolation of clonal cell lines by dilution
• tIMInG 2-3 h hands-on; 2-3 weeks expansion  crItIcal As cell types can vary greatly in their response to FACS, clonal-density dilution or other isolation procedures, literature specific to the cell type of interest should be consulted.
66|
Dissociate the cells from the transfected wells (Steps 11 or 28) 48 h after transfection. Take care to dissociate to single cells. A cell strainer (Step 60) can be used to prevent clumping of cells.
67|
Count the number of cells from each 24-well plate, and serially dilute them in D10 medium to a final concentration of 0.5 cells per 100 µl to reduce the likelihood of having multiple cells per well. We recommend using 60 cells in 12 ml of D10 medium for each 96-well plate, and plating at least two 96-well plates for each transfected population.  crItIcal step Single-cell dissociation and accurate count of cell number are critical for clonal dilution. We recommend examining the dissociated cells under a microscope to ensure successful dissociation and recounting cells at an intermediate serial dilution stage to ensure accuracy. ? trouBlesHootInG 68| Multichannel-pipette 100 µl of diluted cells to each well of a 96-well plate. The remaining cell suspension can be kept and used for genotyping at the population level to gauge overall modification efficiency.
69|
Inspect the colonies for a clonal appearance ~1 week after plating (rounded colonies radiating from a central point).
Mark off the wells that may have been seeded with multiple cells.
70|
Return the cells to the incubator and allow them to expand for 2-3 weeks. Refeed and replica-plate the cells as needed and as detailed in Steps 64 and 65.
Functional testing: detection of indel mutations by the surVeYor nuclease assay • tIMInG 5-6 h  crItIcal Before assaying the cleavage efficiency of transfected cells, we recommend testing each new SURVEYOR primer on negative (untransfected) control samples for the intended cell type by SURVEYOR nuclease digestion. 84|Visualizing the SURVEYOR reaction. SURVEYOR nuclease digestion products can be visualized on a 2% (wt/vol) agarose gel. For better resolution, products can be run on a 4-20% gradient polyacrylamide TBE gel. Load 10 µl of the product with the recommended loading buffer and run the gel according to the manufacturer's instructions. Typically, we run the gel until the bromophenol blue dye has migrated to the bottom of the gel. Include the DNA ladder and negative (untransfected) controls on the same gel. 91| At 24 h after transfection, isolate the clones by FACS or by serial dilution as described above (Steps 54-70).
71|
92| Expand the cells for 2-3 weeks.
93| Extract the DNA from clonal lines as described above (Steps 71-74) by using 10 µl of QuickExtract solution, and normalize the genomic DNA with ddH 2 O to a final concentration of 100 ng µl − 1 .
94| PCR amplification and analysis of the modified region. For analysis of (micro)deletions, follow option A; for analysis of inversions, follow option B. As with SURVEYOR assays, include a negative (untransfected sample) control. Set up the PCR as follows: 
102|
In the HDR example provided in Figure 6 , a HindIII restriction site was inserted into the EMX1 gene. These are detected by an RFLP analysis of the PCR amplicon: 103| Digest the DNA for 10 min at 37 °C.
104| Run 10 µl of the digested product with loading dye on a 4-20% gradient polyacrylamide TBE gel until the xylene cyanol band has migrated to the bottom of the gel.
105|
Stain the gel with SYBR Gold dye while rocking for 15 min. Be sure to shield the staining solution from light to avoid photobleaching of the dye.
106|
Image and quantify the cleavage products as described above for the SURVEYOR assay section (Steps 86-89).
107| HDR efficiency is estimated by using the following formula: (b + c)/(a + b + c), where a is the integrated intensity for the undigested HDR PCR product, and b and c are the integrated intensities for the HindIII-cut fragments. 122| Run 2-5 µl of PCR product on a 1% (wt/vol) agarose gel to check for single-band product. As with all genomic DNA PCRs, the primers may require additional optimization by adjusting the template concentration, MgCl 2 concentration and/or the annealing temperature. ? trouBlesHootInG 123| Purify the PCRs by using the QIAQuick PCR purification kit and normalize the eluants to 20 ng µl −1 .  pause poInt Purified PCR product can be stored at −20 °C overnight or longer.
108|
124| Nextera XT DNA sample preparation kit. According to the manufacturer's protocol, generate Miseq sequencing-ready libraries with unique bar codes for each sample.
125| Sequence the samples prepared in
Step 124 on the Illumina Miseq according to the Illumina user manual.
126| Analyze sequencing data. By using the expected reference genome sequence, perform indel analysis with read alignment programs such as ClustalW (http://www.clustal.org/), Geneious (http://www.geneious.com/) or by simple sequence analysis scripts.
? trouBlesHootInG Troubleshooting advice can be found in 
antIcIpateD results
We have compiled a list of most-frequently asked questions from our web-based CRISPR discussion forum (discuss.genomeengineering.org) to clarify points of confusion when applying the CRISPR system (Box 3). CRISPR-Cas can be easily multiplexed to facilitate high-efficiency genome editing in mammalian cells: by using two sgRNAs, we were able to demonstrate simultaneous targeting of the human DYRK1A and GRIN2B loci at efficiencies of 65-68% for each locus in HEK 293FT cells (Fig. 5b) . Likewise, a pair of sgRNAs can be used to mediate microdeletions, such as excision of EMX1 exon 3, which we genotyped by PCR at a clonal level (Fig. 5c) . Note that the precise location of exon junctions can vary. We also demonstrate here the use of ssODNs and targeting vector to mediate HDR (Fig. 6a,b) with both WT and the D10A nickase mutant of Cas9 in HEK 293FT and HUES9 cells (Fig. 6c) . Note that we have not been able to detect HDR in HUES9 cells by using Cas9n with a sgRNA, which may be due to low efficiency or a potential difference in repair activities in HUES9 cells. The state of ploidy of the cell type of interest may also affect modification efficiency. However, Cas9n may be paired with two sgRNAs to mediate a DSB and stimulate HDR in HUES9 cells.
Box 3 | Frequently asked questions from the CRISPR Discussion Forum
The following questions are selected from the CRISPR Discussion Forum (discuss.genome-engineering.org).
Q1: Should I use crRNA + tracrRNA or sgRNA? Although we initially reported that sgRNAs with a truncated tracrRNA 3′ tail, sgRNA( + 48), are less effective for gene targeting in mammalian cells than using crRNA and tracrRNA pairs 22 , we have optimized the sgRNA architecture by extending its tracrRNA tail. sgRNA( + 85), used in pSpCas9 vectors, is able to mediate the highest efficiency of genome modification 57 .
Q2: My 20-bp target site does not start with G; can I replace the first base with G? For efficient U6 transcription of sgRNA, a G is preferred at the 5′ position, which corresponds with the first base of the 20-bp guide sequence. For guide sequences that do not begin with a G, we recommend adding an additional G to the 5′ of the guide sequence, resulting in a 21-bp guide sequence (5′-GNNNNNNNNNNNNNNNNNNNN-3′, where the 20 Ns correspond to the 20-bp genomic target sequence immediately upstream of the 5′-NGG PAM). The addition of a 5′ G does not alter the specificity of the sgRNA or affect the efficiency of Cas9 cleavage.
Q3: Should I include the PAM sequence in my sgRNA?
No, the PAM sequence should not be included as a part of the sgRNA. The PAM sequence is located in the genomic target site, immediately following the 20-bp target sequence, but it is not a part of the sgRNA. Only the 20-bp target sequence is used to construct the sgRNA. For S. pyogenes Cas9, the PAM sequence is 5′-NGG.
Q4: Which one is more efficient for mediating HDR, WT Cas9 or Cas9 nickase? WT Cas9 is more efficient at mediating homologous recombination than Cas9 nickase. The efficiency of HDR mediated by Cas9 nickase is highly dependent on the cell type. Although Cas9 nickase can reduce the risk for off-target activity, we suggest testing both WT Cas9 and Cas9 nickase when performing gene targeting experiments.
Q5: Does the CBh promoter in pSpCas9 work in my cell line? The CBh promoter is an altered version of the CAG promoter 69 , and we have validated it in the following cell lines: HEK 293FT, human ESCs, mouse ESCs, HepG2, HeLa and Neuro 2a. For other cell lines, we recommend testing Cas9 expression by using pSpCas9(BB)-2A-GFP and checking for green fluorescence, or staining for Cas9 expression using antibodies against the 3× FLAG epitope that has been fused to the N-term of Cas9.
Q6: Which method of sgRNA expression is more effective, PCR-generated U6-sgRNA expression cassette or pSpCas9 plasmid carrying the appropriate sgRNA?
We have found that the use of pSpCas9 plasmid often results in higher cleavage efficiency. The use of PCR-generated U6-sgRNA expression cassettes allows easy and rapid comparison of sgRNA efficiencies so that the most optimal sgRNA, in terms of both efficiency and specificity, can be identified before subsequent cloning into pSpCas9.
Q7: Can the HDR template (plasmid or ssODN) contain the sgRNA target site?
We have found that it is possible to achieve HDR by using both plasmids and ssODNs that contain the target site. However, single bases can be silently mutated to prevent cleavage of the templates.
